Every Form 4 that Nkarta, Inc. (NKTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NKTX filings page.
Nkarta, Inc. Chief Executive Officer Paul J. Hastings reported an open-market sale of 1,776 shares of common stock at $2.71 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations tied to vesting and settlement of Restricted Stock Units and were not a discretionary trade. After this transaction, Hastings directly holds 390,247 shares of Nkarta common stock, which includes 2,000 shares acquired under the company’s 2020 Employee Stock Purchase Plan on May 31, 2026.
Nkarta, Inc. reported a Form 4 showing a compensation-related stock option grant connected to RA Capital–affiliated entities. An option over 37,000 shares of common stock was awarded with a $2.46 exercise price, vesting 100% on June 10, 2027 or before the first annual stockholder meeting after grant, with accelerated vesting upon a change in control, death, or disability. The option is held by Dr. Scheiner for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund LP, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Nkarta, Inc. director Ali Behbahani reported receiving a stock option grant covering 37,000 shares of common stock. The option has an exercise price of $2.46 per share and expires on June 9, 2036.
All 37,000 shares subject to the option vest 100% on the first to occur of June 10, 2027 or the day immediately before the first annual stockholder meeting after the grant date. The award becomes fully vested earlier if there is a defined change in control of Nkarta or if Behbahani’s service ends due to death or disability. Following this grant, he directly holds options for 37,000 underlying shares.
Nkarta, Inc. director George Simeon received a stock option grant for 37,000 shares of Common Stock. The option has an exercise price of $2.4600 per share and expires on June 9, 2036. All shares subject to the option vest 100% on the earlier of June 10, 2027 or the day immediately before the first annual meeting of stockholders after the grant date. The award becomes fully vested if there is a described "change in control" or if Simeon’s service ends because of death or "disability" as defined in the award agreement.
Nkarta, Inc. director George Vratsanos received a grant of stock options covering 37,000 shares of common stock at an exercise price of $2.46 per share. This is a compensation-related award, not an open-market purchase.
All 37,000 option shares vest 100% on the earlier of June 10, 2027 or the day immediately before the first annual stockholder meeting following the grant date. The options become fully vested earlier if there is a qualifying change in control of Nkarta or if Vratsanos separates from service due to death or disability before that time.
Nkarta, Inc. director Zachary Scheiner reported an award of stock options covering 37,000 shares of common stock at an exercise price of $2.46 per share. The options vest 100% on the earlier of June 10, 2027 or the day before the first annual stockholder meeting after the grant, and expire on June 9, 2036. Under an arrangement with RA Capital Management, L.P., Scheiner holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P. and disclaims beneficial ownership of the option and underlying shares.
Nkarta, Inc. director Patterson Leone D received a grant of stock options covering 37,000 shares of common stock at an exercise price of $2.46 per share. The options vest 100% on the earlier of June 10, 2027 or the day before the first annual stockholder meeting after the grant date.
These options expire on June 9, 2036 and will fully vest if there is a qualifying change in control, or if the director’s service ends due to death or disability. This filing reflects a compensation-related award rather than open-market buying or selling.
Nkarta, Inc. director Michael Dybbs received a stock option grant covering 37,000 shares of common stock. The option has an exercise price of $2.46 per share and expires on June 9, 2036.
All 37,000 shares vest 100% on the earlier of June 10, 2027 or the day before the first annual stockholder meeting after the grant date, and become fully vested sooner if there is a change in control of Nkarta, or if Dybbs separates from service due to death or disability.
Nkarta, Inc. director Angela Thedinga received a grant of stock options covering 37,000 shares of common stock at an exercise price of $2.46 per share. The options vest 100% on the earlier of June 10, 2027 or the day before the first annual stockholder meeting after the grant date, with full vesting upon certain change in control, death, or disability events.
Nkarta, Inc. insider transaction: Chief Executive Officer and director Paul J. Hastings reported an automatic sale of 26,046 shares of Nkarta common stock on 01/15/2026 at a price of $2.07 per share. The filing explains that these shares were sold to satisfy tax withholding obligations arising from the vesting and settlement of Restricted Stock Units and that the transaction was not a discretionary trade by the reporting person. Following this tax-related sale, Hastings beneficially owned 390,023 shares of Nkarta common stock directly.
Nkarta, Inc. (NKTX) president Mahmood Nadir reported a small sale of company stock related to tax withholding. On January 15, 2026, he sold 5,649 shares of Common Stock at $2.07 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, and were not a discretionary sale. After this transaction, he directly beneficially owned 167,727 shares of Nkarta common stock.
Nkarta, Inc. insider Rose Shawn Marshall, the company’s Chief Medical Officer and Head of Research & Development, reported new equity awards on a Form 4. On January 6, 2026, Marshall received 70,000 shares of Common Stock in the form of Restricted Stock Units, granted at $0 per share. These RSUs vest in four equal annual installments beginning on January 14, 2027, with each RSU representing one share of Nkarta common stock.
On the same date, Marshall was also granted a stock option to buy 139,000 shares of Common Stock at an exercise price of $1.93 per share. This option is scheduled to vest in 48 equal monthly installments, based on continued service after January 14, 2026, and expires on January 5, 2036. Both awards are reported as directly owned following these transactions.
Nkarta, Inc. reported an equity award to its President, Mahmood Nadir, in the form of both restricted stock units and stock options. On 01/06/2026, he received 80,000 shares of Common Stock as Restricted Stock Units, which are scheduled to vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Common Stock.
On the same date, he was also granted a stock option covering 160,000 shares of Common Stock at an exercise price of $ 1.93 per share, expiring on 01/05/2036. This option is scheduled to vest in 48 equal monthly installments following January 14, 2026, contingent on continued service. After these transactions, he directly beneficially owned 173,376 shares of Common Stock and 160,000 derivative securities.
Nkarta, Inc. reported an insider equity award for Chief Executive Officer and director Paul J. Hastings. On January 6, 2026, he received 94,000 shares of Common Stock in the form of Restricted Stock Units, granted at a price of $0. These RSUs vest in four equal annual installments beginning on January 14, 2027, with each RSU convertible into one share of Common Stock.
On the same date, Hastings was also granted a stock option for 562,000 shares of Common Stock at an exercise price of $1.93 per share, with no cost reported for the grant itself. This option is scheduled to vest in 48 equal monthly installments following January 14, 2026. After these transactions, he beneficially owned 416,069 shares of Common Stock directly, along with the 562,000 stock options. The share total includes 2,000 shares acquired under Nkarta’s 2020 Employee Stock Purchase Plan on November 30, 2025.